Literature DB >> 1233232

Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses.

M Eichelbaum, K Ekbom, L Bertilsson, V A Ringberger, A Rane.   

Abstract

Carbamazepine (Tegretol) was administered orally to four patients as a single dose, and one week later three times daily for 15-21 days. The plasma half-lives of the drug were shorter in all patients after multiple doses (20.9 +/- 5.0 hours) than after the initial single dose (35.6 +/- 15.3 hours). During the multiple dose the plasma concentrations of the metabolite carbamazepine-10,11-epoxide followed those of the parent drug. The steady-state plasma concentrations expected during multiple doses were calculated from the pharmacokinetic parameters obtained in the single dose studies. The calculated levels were higher (17.2+/-7.2 mug/ml) than the observed maximal concentrations (8.4+/-1.6 mug/ml on day 4), which were obtained 3-4 days after starting the multiple doses. The levels tended to decrease further during the experimental period. The results suggest that carbamazepine induces its own metabolism in man.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1233232     DOI: 10.1007/bf00562659

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  12 in total

1.  Determination of carbamazepine and its epoxide metabolite in plasma by high-speed liquid chromatography.

Authors:  M Eichelbaum; L Bertilsson
Journal:  J Chromatogr       Date:  1975-01-14

2.  Quantitative determination of carbamazepine in plasma by mass fragmentography.

Authors:  L Palmér; L Bertilsson; P Collste; M Rawlins
Journal:  Clin Pharmacol Ther       Date:  1973 Sep-Oct       Impact factor: 6.875

3.  Influence of phenobarbital and diphenylhydantoin on plasma carbamazepine levels in patients with epilepsy.

Authors:  J Christiansen; M Dam
Journal:  Acta Neurol Scand       Date:  1973       Impact factor: 3.209

4.  Carbamazepine in the treatment of tabetic lightning pains.

Authors:  K Ekbom
Journal:  Arch Neurol       Date:  1972-04

5.  Mass spectrometric characterization of carbamazepine-10,11-epoxide, a carbamazepine metabolite isolated from human urine.

Authors:  A Frigerio; R Fanelli; P Biandrate; G Passerini; P L Morselli; S Garattini
Journal:  J Pharm Sci       Date:  1972-07       Impact factor: 3.534

6.  Shortcomings in pharmacokinetic analysis by conceiving the body to exhibit properties of a single compartment.

Authors:  S Riegelman; J C Loo; M Rowland
Journal:  J Pharm Sci       Date:  1968-01       Impact factor: 3.534

7.  Carbamazepine for epilepsy. A controlled prospective evaluation.

Authors:  J J Cereghino; J T Brock; J C Van Meter; J K Penry; L D Smith; B G White
Journal:  Neurology       Date:  1974-05       Impact factor: 9.910

8.  Blood levels of drug at the equilibrium state after multiple dosing.

Authors:  J G Wagner; J I Northam; C D Alway; O S Carpenter
Journal:  Nature       Date:  1965-09-18       Impact factor: 49.962

9.  Plasma levels of carbamazepine and carbamazepine-10,11-epoxide during treatment of epilepsy.

Authors:  M Eichelbaum; L Bertilsson; L Lund; L Palmér; F Sjöqvist
Journal:  Eur J Clin Pharmacol       Date:  1976-03-22       Impact factor: 2.953

10.  Concentration of carbamazepine (Tegretol) in serum and in cerebrospinal fluid in patients with epilepsy.

Authors:  S I Johannessen; R E Strandjord
Journal:  Epilepsia       Date:  1973-12       Impact factor: 5.864

View more
  54 in total

Review 1.  Pharmacokinetics of drugs in overdose.

Authors:  Y J Sue; M Shannon
Journal:  Clin Pharmacokinet       Date:  1992-08       Impact factor: 6.447

2.  Effect of denzimol on carbamazepine and carbamazepine-10,11-epoxide concentrations in serum, liver, spleen and different brain regions of the rat: an inhibitory metabolic interaction.

Authors:  P N Patsalos; M S Alavijeh; W Brownhill; P T Lascelles
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-01       Impact factor: 3.000

3.  Early stage autoinduction of carbamazepine metabolism in humans.

Authors:  I Bernus; R G Dickinson; W D Hooper; M J Eadie
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

4.  Brain concentrations of carbamazepine and carbamazepine-10,11-epoxide in epileptic patients.

Authors:  M L Friis; J Christiansen; E F Hvidberg
Journal:  Eur J Clin Pharmacol       Date:  1978-11-09       Impact factor: 2.953

5.  Time course of carbamazepine self-induction.

Authors:  P J McNamara; W A Colburn; M Gibaldi
Journal:  J Pharmacokinet Biopharm       Date:  1979-02

6.  Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy.

Authors:  Yogita Ghodke Puranik; Angela K Birnbaum; Susan E Marino; Ghada Ahmed; James C Cloyd; Rory P Remmel; Ilo E Leppik; Jatinder K Lamba
Journal:  Pharmacogenomics       Date:  2013-01       Impact factor: 2.533

7.  Comparison of the pharmacokinetics of diazepam after single and subchronic doses.

Authors:  U Klotz; K H Antonin; P R Bieck
Journal:  Eur J Clin Pharmacol       Date:  1976-06-15       Impact factor: 2.953

8.  Salivary concentrations and plasma protein binding of carbamazepine and carbamazepine 10,11-epoxide in epileptic patients.

Authors:  J J MacKichan; P K Duffner; M E Cohen
Journal:  Br J Clin Pharmacol       Date:  1981-07       Impact factor: 4.335

9.  Carbamazepine metabolism in man. Induction and pharmacogenetic aspects.

Authors:  M Eichelbaum; T Tomson; G Tybring; L Bertilsson
Journal:  Clin Pharmacokinet       Date:  1985 Jan-Feb       Impact factor: 6.447

Review 10.  Anticonvulsant drugs. An update.

Authors:  M J Eadie
Journal:  Drugs       Date:  1984-04       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.